Molly Harper, Chief Business Officer of Synlogic, a biotechnology company that went public in 2021 through a reverse merger with Mirna Therapeutics raising an additional $40M after $100M in venture capital funding. Molly is also a member of the Board of Directors for Catalyst Pharmaceuticals and PreciseDX. Molly attended Wharton for her MBA, Healthcare Management, and Bachelor of Arts from Cornell University.